Daiichi announces first subject dosing in Enhertu trial for endometrial cancer
Daiichi Sankyo has announced the first subject dosing in the Phase III DESTINYEndometrial01 trial of Enhertu (trastuzumab deruxtecan) plus rilvegostomig…
Oncology
-
-
Iambic concludes dose escalation in Phase I/Ib trial of IAM1363
US-based Iambic Therapeutics has concluded the dose escalation phase in its multi-centre Phase I/Ib trial of a brain-penetrant small molecule…
-
Moleculin announces efficacy results from trial of Annamycin for STS lung mets
Moleculin Biotech has announced encouraging topline efficacy outcomes from its US Phase IB/II trial, MB-107, of Annamycin for soft tissue…
-
ASCO25: Imunon shares positive results from trial of IMNN-001 for ovarian cancer
US-based biotechnology company Imunon has reported positive results from its Phase II OVATION 2 trial of IMNN-001 for ovarian cancer.…
-
Byondis begins dosing subjects in Phase I trial of BYON4228 for solid tumours
Dutch pharmaceutical company Byondis has begun dosing subjects in a Phase I trial of BYON4228 for treating advanced or metastatic…
-
Implementing pragmatic approaches for the patients and sites in oncology trials
Is the clinical trials field doing enough to centre the needs and concerns of patients in research? That was the…
-
ASCO25: OnCusp reports positive initial Phase Ia data from trial of CUSP06
US-based OnCusp Therapeutics has reported initial Phase Ia data from its ongoing multicentre dose escalation and expansion Phase I trial…
-
Novartis reports topline outcomes from trial of Pluvicto for prostate cancer
Novartis has reported topline outcomes from the Phase III PSMAddition trial’s pre-specified interim analysis, where Pluvicto (lutetium (177Lu) vipivotide tetraxetan),…
-
ASCO25: AstraZeneca’s novel trial design for camizestrant pays off in breast cancer
AstraZeneca has presented results for the SERENA-6 trial at the American Society for Medical Oncology (ASMO)'s 2025 conference, held in…
-
ASCO25: Johnson & Johnson reports data from Phase I trial of prostate cancer drug
US-based pharmaceutical company Johnson & Johnson has reported data from a Phase I trial of its bispecific antibody, pasritamig, for…
